News & Views
Telix today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational…
Read more
Telix today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has…
Read more
Telix invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate…
Read more
Telix today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry, defining the potential prognostic value of PSMA-PET imaging through artificial intelligence…
Read more
News,
As a resource for analysts and investors, Telix has published a clinical data summary for TLX591-Tx (lutetium-177 rosopatamab tetraxetan), its investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC)….
Read more
Telix today announces its financial results for the year ended December 31,…
Read more
Telix today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging…
Read moreTelix advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026…
Read more
Telix today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in…
Read more
Telix provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4…
Read more